Gilead Sciences (GILD) 100.65 $GILD
2 Reasons Gilead Sciences Suffered Through a Rough September
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 09, 8:07AM CDT
Shareholders of biotech blue-chip giant Gilead Sciences suffered through a rough September, with Gilead's stock dipping as much as 10% before ending the month lower by nearly 7%, according to S&P Capital IQ . In dollar terms, Gilead witnessed...
GILD: 100.65 (-0.16)
'Fast Money' Recap: Avoid Alcoa on Its Disappointing Earnings
at The Street - Fri Oct 09, 4:00AM CDT
The trading panel discussed biotech stocks and Netflix' subscription rate increase.
NFLX: 113.33 (-1.60), BIIB: 269.16 (-10.72), AA: 10.26 (-0.75), SPY: 201.33 (+0.12), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), RGLS: 6.86 (+0.29), CELG: 117.38 (-0.59)
Gilead Is About to Disappoint Investors -- but for All the Right Reasons
George Budwell, The Motley Fool - Motley Fool - Thu Oct 08, 8:06PM CDT
After a brief summer spike, Gilead Sciences stock has given back most of its gains this year and continues to be seemingly locked into a long-term relationship with $100 a share. The problem is that Wall Street appears to be becoming increasingly...
GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), ABBV: 55.64 (-0.40)
3 Pharma Stocks With Big Margins of Safety
Brian Feroldi, Sean Williams, and George Budwell, The Motley Fool - Motley Fool - Thu Oct 08, 3:43PM CDT
Healthcare stocks have had a rough past couple of months. The Vanguard Health Care ETF (VHT) , an exchange traded fund that tracks the returns of 342 stocks from the healthcare sector, is down more than 17% from its recent 52-week high, which could...
JNJ: 95.37 (+0.29), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), ABBV: 55.64 (-0.40), VHT: 125.98 (+0.73)
Stocks Rally as March Rate Hike Most Likely
at The Street - Thu Oct 08, 3:06PM CDT
Stocks break free of range-bound trading in the final hour Thursday as a March rate hike grows more likely.
AA: 10.26 (-0.75), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DPZ: 105.38 (+2.74), DB: 29.34 (+0.95), AMGN: 149.59 (-0.31), IBB: 308.45 (+1.25), EMC: 27.86 (+0.68), LL: 18.84 (+2.42)
Stocks Rise as Investors Interpret Fed Minutes as Dovish
at The Street - Thu Oct 08, 1:55PM CDT
Equities turn higher in late afternoon trading Thursday as investors interpret the Federal Reserve's minutes of its September meeting as dovish.
AA: 10.26 (-0.75), SHAK: 44.05 (-2.17), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DPZ: 105.38 (+2.74), DB: 29.34 (+0.95), AMGN: 149.59 (-0.31), IBB: 308.45 (+1.25), FCAU: 15.67 (+0.17), EMC: 27.86 (+0.68), LL: 18.84 (+2.42)
Everything Wants to Go Up at the Same Time
at The Street - Thu Oct 08, 12:18PM CDT
This rolling bear market can be deceptive.
MMM: 149.90 (+0.42), GE: 28.07 (+0.04), CLX: 120.52 (+0.34), HON: 101.16 (+0.09), KMB: 114.73 (+0.93), PSTG: 16.60 (+0.67), M: 51.00 (-0.47), XOM: 79.26 (-0.77), BWLD: 196.14 (-1.07), JNPR: 29.40 (-0.40), JACK: 77.41 (+1.62), ECA: 8.76 (-0.26), IBM: 152.39 (+0.11), CMG: 732.93 (-1.84), TGT: 78.88 (+0.19), COST: 153.97 (+2.31), GOOGL: 671.24 (+4.24), EMC: 27.86 (+0.68), TWTR: 30.85 (+0.53), AAPL: 112.12 (+2.62), MBLY: 49.27 (+1.38), UNP: 97.04 (-0.01), CSCO: 27.91 (unch), GPRO: 29.08 (+1.48), AMZN: 539.80 (+6.64), SWKS: 79.50 (+0.07), FB: 93.24 (+0.77), BA: 139.70 (+0.66), HPQ: 29.30 (+0.12), DIN: 91.64 (+0.08), CELG: 117.38 (-0.59), DENN: 11.19 (+0.09), NFLX: 113.33 (-1.60), GILD: 100.65 (-0.16), MCD: 102.76 (-0.19), PG: 74.48 (+0.08), MRO: 19.59 (-0.59), CVX: 89.57 (-0.34)
Stock Market News for October 08, 2015
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session in the green boosted by gains in biotechnology companies
KMI: 32.35 (-0.33), BIIB: 269.16 (-10.72), MON: 89.70 (+0.45), COP: 56.10 (-0.18), AMGN: 149.59 (-0.31), BA: 139.70 (+0.66), CELG: 117.38 (-0.59), LYB: 95.45 (-2.05), GILD: 100.65 (-0.16), DD: 56.18 (+0.05), CVX: 89.57 (-0.34), DOW: 47.08 (-0.71), REGN: 503.92 (+12.71), ECL: 120.54 (+0.01), YUM: 70.25 (+2.79)
Biogen Caused Biotech Collapse but Might Also Lead Stocks Higher
at The Street - Thu Oct 08, 7:49AM CDT
Biogen has the opportunity to make amends for its second-quarter earnings blow-up when it reports third-quarter earnings in two weeks.
BIIB: 269.16 (-10.72), GILD: 100.65 (-0.16), IBB: 308.45 (+1.25), AMGN: 149.59 (-0.31), CELG: 117.38 (-0.59)
'Mad Money' Lightning Round: Buy, Buy, Buy Gilead Sciences
at The Street - Thu Oct 08, 5:00AM CDT
Cramer like Union Pacific, Raytheon and Martin Marietta Materials but thinks Breitburn Energy Partners is too dangerous.
MLM: 165.07 (+2.01), GILD: 100.65 (-0.16), RTN: 111.46 (-0.19), BBEP: 2.78 (-0.01), FGP: 20.69 (-0.26), UNP: 97.04 (-0.01), URI: 70.76 (+0.23)
Jim Cramer's 'Mad Money' Recap: Watching China Warily, Again
at The Street - Wed Oct 07, 7:08PM CDT
China's stock market has been closed for a holiday and U.S. stocks have started to respond, Cramer says. But what happens if China has a bad day Thursday?
MLM: 165.07 (+2.01), JOY: 17.94 (-0.57), GE: 28.07 (+0.04), CLX: 120.52 (+0.34), NKE: 124.94 (+0.03), RTN: 111.46 (-0.19), FCX: 13.49 (+0.03), KMB: 114.73 (+0.93), BBEP: 2.78 (-0.01), WYNN: 75.40 (-0.51), ACRS: 12.50 (+1.45), ALKS: 60.82 (+0.92), EDGE: 17.60 (-0.02), PEP: 99.47 (+0.50), PBR: 5.67 (-0.01), GILD: 100.65 (-0.16), NVCR: 21.02 (+2.08), FGP: 20.69 (-0.26), UNP: 97.04 (-0.01), URI: 70.76 (+0.23), YUM: 70.25 (+2.79)
Bristol-Myers Gets Priority Review for HCV Drug Daklinza
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 2:10PM CDT
Bristol-Myers Squibb (BMY) announced that three of its supplemental New Drug Applications seeking label expansion for hepatitis C drug, Daklinza, will be reviewed on a priority basis by the FDA.
GILD: 100.65 (-0.16), AZN: 32.23 (-0.16), ABBV: 55.64 (-0.40), BMY: 61.44 (+0.93)
BetterInvesting Top 100 Dropped 2.7% in September; 5-Year Increase Almost 14%
PR Newswire - Wed Oct 07, 11:31AM CDT
Through Sept. 30, the BetterInvesting Top 100 Index (BIXX), reflecting the portfolios of Main Street investors, increased by 13.5 percent annually for the previous five years, versus 13.8 percent for the Standard & Poor's 500 Equal-Weight Index (based on a total return for both indexes in which dividends are reinvested).
GILD: 100.65 (-0.16), DIS: 105.56 (+0.95), AAPL: 112.12 (+2.62)
Gilead (GILD) Stock: Looking at the Long Side
at The Street - Wed Oct 07, 10:33AM CDT
The technicals are good, and traders can look at the stock again from the long side.
GILD: 100.65 (-0.16)
Gilead: Improving Lives, Improving Stock
at The Street - Wed Oct 07, 10:03AM CDT
The technicals are good, and traders can look at the stock again from the long side.
GILD: 100.65 (-0.16)
Recession-Proofing Your Portfolio
at The Street - Wed Oct 07, 8:41AM CDT
The outlook on the U.S. economy is unclear, with recent data demonstrating too many contradictions: job growth remains weak, though consumer spending is strong.
GE: 28.07 (+0.04), DLTR: 63.36 (+1.28), GILD: 100.65 (-0.16), PFE: 33.24 (+0.15), MCD: 102.76 (-0.19), XOM: 79.26 (-0.77), DG: 67.23 (+1.03), CAT: 71.30 (-0.54), KORS: 42.59 (-0.92), MO: 56.81 (+0.44), PG: 74.48 (+0.08), INTC: 32.14 (-0.38)
Biotech's Bloodbath Is Ridiculous; Here's Why
George Budwell, The Motley Fool - Motley Fool - Wed Oct 07, 7:43AM CDT
Biotech has had an absolutely terrible time over the last few months, with most of the top dogs in the industry seeing their share prices get some pretty ugly haircuts: GILD data by YCharts . The odd and perhaps ridiculous part of...
GILD: 100.65 (-0.16), CELG: 117.38 (-0.59)
Here we go again: Earnings season begins with the 3rd consecutive quarter of negative expectations
ESTMZ - Wed Oct 07, 7:16AM CDT
Earnings season for the third quarter of 2015 unofficially kicks off on Thursday when Alcoa reports. Similar to the last two quarters, we head into the season with negative top and bottom-line growth expectations for the S&P 500… but as anyone...
BIIB: 269.16 (-10.72), F: 14.97 (-0.02), AA: 10.26 (-0.75), MON: 89.70 (+0.45), GILD: 100.65 (-0.16), FB: 93.24 (+0.77), STZ: 136.89 (+0.20), GM: 32.95 (-0.48), GOOGL: 671.24 (+4.24), HPQ: 29.30 (+0.12), SNDK: 62.36 (-1.75), YUM: 70.25 (+2.79), PEP: 99.47 (+0.50)
Drug Stocks' Earnings Power Won't Go Away
at The Street - Wed Oct 07, 4:23AM CDT
Before you sell them, ask yourself at what multiple you sell.
AGN: 274.84 (-1.32), JNJ: 95.37 (+0.29), ABT: 41.89 (+0.73), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), RCPT: 231.96 (-0.03), TEVA: 58.96 (-0.28), REGN: 503.92 (+12.71), CELG: 117.38 (-0.59)
2 Reasons Gilead Sciences Suffered Through a Rough September
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 09, 8:07AM CDT
Shareholders of biotech blue-chip giant Gilead Sciences suffered through a rough September, with Gilead's stock dipping as much as 10% before ending the month lower by nearly 7%, according to S&P Capital IQ . In dollar terms, Gilead witnessed...
GILD: 100.65 (-0.16)
'Fast Money' Recap: Avoid Alcoa on Its Disappointing Earnings
at The Street - Fri Oct 09, 4:00AM CDT
The trading panel discussed biotech stocks and Netflix' subscription rate increase.
NFLX: 113.33 (-1.60), BIIB: 269.16 (-10.72), AA: 10.26 (-0.75), SPY: 201.33 (+0.12), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), RGLS: 6.86 (+0.29), CELG: 117.38 (-0.59)
Gilead Is About to Disappoint Investors -- but for All the Right Reasons
George Budwell, The Motley Fool - Motley Fool - Thu Oct 08, 8:06PM CDT
After a brief summer spike, Gilead Sciences stock has given back most of its gains this year and continues to be seemingly locked into a long-term relationship with $100 a share. The problem is that Wall Street appears to be becoming increasingly...
GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), ABBV: 55.64 (-0.40)
3 Pharma Stocks With Big Margins of Safety
Brian Feroldi, Sean Williams, and George Budwell, The Motley Fool - Motley Fool - Thu Oct 08, 3:43PM CDT
Healthcare stocks have had a rough past couple of months. The Vanguard Health Care ETF (VHT) , an exchange traded fund that tracks the returns of 342 stocks from the healthcare sector, is down more than 17% from its recent 52-week high, which could...
JNJ: 95.37 (+0.29), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), ABBV: 55.64 (-0.40), VHT: 125.98 (+0.73)
Stocks Rally as March Rate Hike Most Likely
at The Street - Thu Oct 08, 3:06PM CDT
Stocks break free of range-bound trading in the final hour Thursday as a March rate hike grows more likely.
AA: 10.26 (-0.75), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DPZ: 105.38 (+2.74), DB: 29.34 (+0.95), AMGN: 149.59 (-0.31), IBB: 308.45 (+1.25), EMC: 27.86 (+0.68), LL: 18.84 (+2.42)
Stocks Rise as Investors Interpret Fed Minutes as Dovish
at The Street - Thu Oct 08, 1:55PM CDT
Equities turn higher in late afternoon trading Thursday as investors interpret the Federal Reserve's minutes of its September meeting as dovish.
AA: 10.26 (-0.75), SHAK: 44.05 (-2.17), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), PFE: 33.24 (+0.15), DPZ: 105.38 (+2.74), DB: 29.34 (+0.95), AMGN: 149.59 (-0.31), IBB: 308.45 (+1.25), FCAU: 15.67 (+0.17), EMC: 27.86 (+0.68), LL: 18.84 (+2.42)
Everything Wants to Go Up at the Same Time
at The Street - Thu Oct 08, 12:18PM CDT
This rolling bear market can be deceptive.
MMM: 149.90 (+0.42), GE: 28.07 (+0.04), CLX: 120.52 (+0.34), HON: 101.16 (+0.09), KMB: 114.73 (+0.93), PSTG: 16.60 (+0.67), M: 51.00 (-0.47), XOM: 79.26 (-0.77), BWLD: 196.14 (-1.07), JNPR: 29.40 (-0.40), JACK: 77.41 (+1.62), ECA: 8.76 (-0.26), IBM: 152.39 (+0.11), CMG: 732.93 (-1.84), TGT: 78.88 (+0.19), COST: 153.97 (+2.31), GOOGL: 671.24 (+4.24), EMC: 27.86 (+0.68), TWTR: 30.85 (+0.53), AAPL: 112.12 (+2.62), MBLY: 49.27 (+1.38), UNP: 97.04 (-0.01), CSCO: 27.91 (unch), GPRO: 29.08 (+1.48), AMZN: 539.80 (+6.64), SWKS: 79.50 (+0.07), FB: 93.24 (+0.77), BA: 139.70 (+0.66), HPQ: 29.30 (+0.12), DIN: 91.64 (+0.08), CELG: 117.38 (-0.59), DENN: 11.19 (+0.09), NFLX: 113.33 (-1.60), GILD: 100.65 (-0.16), MCD: 102.76 (-0.19), PG: 74.48 (+0.08), MRO: 19.59 (-0.59), CVX: 89.57 (-0.34)
Stock Market News for October 08, 2015
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session in the green boosted by gains in biotechnology companies
KMI: 32.35 (-0.33), BIIB: 269.16 (-10.72), MON: 89.70 (+0.45), COP: 56.10 (-0.18), AMGN: 149.59 (-0.31), BA: 139.70 (+0.66), CELG: 117.38 (-0.59), LYB: 95.45 (-2.05), GILD: 100.65 (-0.16), DD: 56.18 (+0.05), CVX: 89.57 (-0.34), DOW: 47.08 (-0.71), REGN: 503.92 (+12.71), ECL: 120.54 (+0.01), YUM: 70.25 (+2.79)
Biogen Caused Biotech Collapse but Might Also Lead Stocks Higher
at The Street - Thu Oct 08, 7:49AM CDT
Biogen has the opportunity to make amends for its second-quarter earnings blow-up when it reports third-quarter earnings in two weeks.
BIIB: 269.16 (-10.72), GILD: 100.65 (-0.16), IBB: 308.45 (+1.25), AMGN: 149.59 (-0.31), CELG: 117.38 (-0.59)
'Mad Money' Lightning Round: Buy, Buy, Buy Gilead Sciences
at The Street - Thu Oct 08, 5:00AM CDT
Cramer like Union Pacific, Raytheon and Martin Marietta Materials but thinks Breitburn Energy Partners is too dangerous.
MLM: 165.07 (+2.01), GILD: 100.65 (-0.16), RTN: 111.46 (-0.19), BBEP: 2.78 (-0.01), FGP: 20.69 (-0.26), UNP: 97.04 (-0.01), URI: 70.76 (+0.23)
Jim Cramer's 'Mad Money' Recap: Watching China Warily, Again
at The Street - Wed Oct 07, 7:08PM CDT
China's stock market has been closed for a holiday and U.S. stocks have started to respond, Cramer says. But what happens if China has a bad day Thursday?
MLM: 165.07 (+2.01), JOY: 17.94 (-0.57), GE: 28.07 (+0.04), CLX: 120.52 (+0.34), NKE: 124.94 (+0.03), RTN: 111.46 (-0.19), FCX: 13.49 (+0.03), KMB: 114.73 (+0.93), BBEP: 2.78 (-0.01), WYNN: 75.40 (-0.51), ACRS: 12.50 (+1.45), ALKS: 60.82 (+0.92), EDGE: 17.60 (-0.02), PEP: 99.47 (+0.50), PBR: 5.67 (-0.01), GILD: 100.65 (-0.16), NVCR: 21.02 (+2.08), FGP: 20.69 (-0.26), UNP: 97.04 (-0.01), URI: 70.76 (+0.23), YUM: 70.25 (+2.79)
Bristol-Myers Gets Priority Review for HCV Drug Daklinza
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 2:10PM CDT
Bristol-Myers Squibb (BMY) announced that three of its supplemental New Drug Applications seeking label expansion for hepatitis C drug, Daklinza, will be reviewed on a priority basis by the FDA.
GILD: 100.65 (-0.16), AZN: 32.23 (-0.16), ABBV: 55.64 (-0.40), BMY: 61.44 (+0.93)
BetterInvesting Top 100 Dropped 2.7% in September; 5-Year Increase Almost 14%
PR Newswire - Wed Oct 07, 11:31AM CDT
Through Sept. 30, the BetterInvesting Top 100 Index (BIXX), reflecting the portfolios of Main Street investors, increased by 13.5 percent annually for the previous five years, versus 13.8 percent for the Standard & Poor's 500 Equal-Weight Index (based on a total return for both indexes in which dividends are reinvested).
GILD: 100.65 (-0.16), DIS: 105.56 (+0.95), AAPL: 112.12 (+2.62)
Gilead (GILD) Stock: Looking at the Long Side
at The Street - Wed Oct 07, 10:33AM CDT
The technicals are good, and traders can look at the stock again from the long side.
GILD: 100.65 (-0.16)
Gilead: Improving Lives, Improving Stock
at The Street - Wed Oct 07, 10:03AM CDT
The technicals are good, and traders can look at the stock again from the long side.
GILD: 100.65 (-0.16)
Recession-Proofing Your Portfolio
at The Street - Wed Oct 07, 8:41AM CDT
The outlook on the U.S. economy is unclear, with recent data demonstrating too many contradictions: job growth remains weak, though consumer spending is strong.
GE: 28.07 (+0.04), DLTR: 63.36 (+1.28), GILD: 100.65 (-0.16), PFE: 33.24 (+0.15), MCD: 102.76 (-0.19), XOM: 79.26 (-0.77), DG: 67.23 (+1.03), CAT: 71.30 (-0.54), KORS: 42.59 (-0.92), MO: 56.81 (+0.44), PG: 74.48 (+0.08), INTC: 32.14 (-0.38)
Biotech's Bloodbath Is Ridiculous; Here's Why
George Budwell, The Motley Fool - Motley Fool - Wed Oct 07, 7:43AM CDT
Biotech has had an absolutely terrible time over the last few months, with most of the top dogs in the industry seeing their share prices get some pretty ugly haircuts: GILD data by YCharts . The odd and perhaps ridiculous part of...
GILD: 100.65 (-0.16), CELG: 117.38 (-0.59)
Here we go again: Earnings season begins with the 3rd consecutive quarter of negative expectations
ESTMZ - Wed Oct 07, 7:16AM CDT
Earnings season for the third quarter of 2015 unofficially kicks off on Thursday when Alcoa reports. Similar to the last two quarters, we head into the season with negative top and bottom-line growth expectations for the S&P 500… but as anyone...
BIIB: 269.16 (-10.72), F: 14.97 (-0.02), AA: 10.26 (-0.75), MON: 89.70 (+0.45), GILD: 100.65 (-0.16), FB: 93.24 (+0.77), STZ: 136.89 (+0.20), GM: 32.95 (-0.48), GOOGL: 671.24 (+4.24), HPQ: 29.30 (+0.12), SNDK: 62.36 (-1.75), YUM: 70.25 (+2.79), PEP: 99.47 (+0.50)
Drug Stocks' Earnings Power Won't Go Away
at The Street - Wed Oct 07, 4:23AM CDT
Before you sell them, ask yourself at what multiple you sell.
AGN: 274.84 (-1.32), JNJ: 95.37 (+0.29), ABT: 41.89 (+0.73), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), RCPT: 231.96 (-0.03), TEVA: 58.96 (-0.28), REGN: 503.92 (+12.71), CELG: 117.38 (-0.59)
